cbd esquizofrenia

December 15, 2021 By admin Off

Patients often ask me about medical marijuana. I advise my patients with a family or personal history of bipolar disorder and schizophrenia to avoid THC, to avoid most of the over-the-counter products except, perhaps, from a regulated state dispensary as we don’t know what’s in that bottle of hemp oil you bought on Amazon, and that there is very little data about CBD for any psychiatric condition. However, more information will be coming like water out of a fire hose. At.

THC is known for causing the psychoactive “high” of the marijuana experience, which can extend to paranoia, but can also perhaps aid pain relief and induce sleep and relaxation, at least the short term. CBD is short for cannabidiol, and it does not cause a high. A form of CBD, Epidiolex, was recently FDA approved for the treatment of seizures associated with certain rare conditions in childhood, and is a schedule V drug (this is relatively low restriction, with schedule I being illegal things like heroin, and schedule II being many prescription opiates and stimulants with higher potential for abuse).

In Massachusetts and several other states, cannabis products (with some regulation) are legal for both medical and recreational use. While cannabis as a plant has hundreds of chemicals called cannabinoids, many of which may have medicinal, toxic, or psychoactive effects, the two we know the most about are THC and CBD.

The latest research and possible problems with the ubiquitous supplement.

Another study of 42 people back in 2012 also showed some benefit for improving both hallucinations/delusions and disordered thinking in schizophrenia. A study of 36 folks with chronic, stable schizophrenia symptoms on a somewhat lower dose of CBD showed no difference between CBD and placebo with either positive effects or any bad side effects other than a little sedation. All told that’s less than 200 people. It’s certainly interesting, perhaps even promising, and while we don’t know precisely how it works, it doesn’t seem to work like any of the other medications used for schizophrenia, and it also doesn’t have many of the side effects of other meds (though without long term studies, we can’t assess longer-term side effects).

Because much of the early research showed that CBD probably attenuated the psychotic effects of THC in different strains of marijuana, most of the completed studies of CBD have been in schizophrenia as an additional treatment on top of standard medications and therapies. The largest was of a randomized controlled trial of 88 people by McGuiare et al showing significant improvement in cognitive processing and lower levels of psychotic symptoms such as hallucinations.

What are the downsides of CBD, besides the expense and the very real possibility of confusing it with cannabis oil? FDA-approved Epidiolex has a warning to watch for liver damage, and large amounts of CBD in mice is toxic to the liver (by a lot, compare 20 mg/kg recommended dose of Epidiolex to 614 mg/kg that typically induced liver damage in the mice. So if you have the means to purchase large amounts of CBD oil, I certainly would not recommend drinking 30 grams of it at a time.

One additional problem exists with CBD. It is a strong cytochrome p450 3A4 inhibitor, which means it has the potential to slow the metabolism (thus increase the dose, perhaps to toxic levels) of 60% of common medications, including many benzodiazepines, antipsychotics, opioids, antibiotics, heart medications, and even meds for organ transplant rejection (see the list of “substrates” on this Wikipedia page.) While that hemp oil gummy you get at the gas station might have 0-1% CBD (but who knows how much?), a stronger product could cause some real problems for people on many different types of medications. As these supplements become more popular and it’s likely there will be some competition between CBD products at the dispensaries vs the FDA approved forms which will be covered in warnings about interactions, it’s very important for doctors and pharmacists to know about these issues.

Hemp-derived CBD oil is also sold as Hemp oil in all sorts of forms over the counter with almost no regulation and at dispensaries in states that have them. You can get anything from gummies to drops to vape oils to dog biscuits. Unless you get the oil from a regulated dispensary (or are somehow prescribed the FDA-approved version), it’s unclear how much CBD oil is actually in the product you are consuming. The real stuff tends to be expensive ($70-120 for a couple of ounces). Another very important thing to know is that cannabis oil, available from dispensaries, is not the same as CBD or cannabidiol oil, and is usually very high in THC. You absolutely do not want to mix up these two substances.

The takeaway is that CBD has real potential to help people with psychiatric conditions, even something as difficult and chronic as schizophrenia. But we have to wait for the science to catch up to any hype before we know for sure.



Method: In an exploratory double-blind parallel-group trial, patients with schizophrenia were randomized in a 1:1 ratio to receive CBD (1000 mg/day; N=43) or placebo (N=45) alongside their existing antipsychotic medication. Participants were assessed before and after treatment using the Positive and Negative Syndrome Scale (PANSS), the Brief Assessment of Cognition in Schizophrenia (BACS), the Global Assessment of Functioning scale (GAF), and the improvement and severity scales of the Clinical Global Impressions Scale (CGI-I and CGI-S).

Objective: Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors assessed the safety and effectiveness of CBD in patients with schizophrenia.

Results: After 6 weeks of treatment, compared with the placebo group, the CBD group had lower levels of positive psychotic symptoms (PANSS: treatment difference=-1.4, 95% CI=-2.5, -0.2) and were more likely to have been rated as improved (CGI-I: treatment difference=-0.5, 95% CI=-0.8, -0.1) and as not severely unwell (CGI-S: treatment difference=-0.3, 95% CI=-0.5, 0.0) by the treating clinician. Patients who received CBD also showed greater improvements that fell short of statistical significance in cognitive performance (BACS: treatment difference=1.31, 95% CI=-0.10, 2.72) and in overall functioning (GAF: treatment difference=3.0, 95% CI=-0.4, 6.4). CBD was well tolerated, and rates of adverse events were similar between the CBD and placebo groups.

Conclusions: These findings suggest that CBD has beneficial effects in patients with schizophrenia. As CBD’s effects do not appear to depend on dopamine receptor antagonism, this agent may represent a new class of treatment for the disorder.

Keywords: Cannabidiol; Clinical Trial; Psychosis; Schizophrenia; Treatment.

Orr, C., Morioka, R., Behan, B., Datwani, S., Doucet, M., Ivanovic, J., . Garavan, H. (2013). Altered resting-state connectivity in adolescent cannabis users. The American Journal of Drug and Alcohol Abuse , 39 , 372-381. doi:10.3109/00952990.2013.848213.

Extein, I. L. y Gold, M. S. (1993). Hypothesized neurochemical models for psychiatric syndromes in alcohol and drug dependence. Journal of Addictive Diseases , 12 , 29-43. doi:10.1300/J069v12n03_04.

Suero-García, C., Martín-Banderas, L. y Holgado, M. (2015). Efecto neuroprotector de los cannabinoides en las enfermedades neurodegenerativas. Ars Pharmaceutica , 56 , 77-87. doi:10.4321/S2340-98942015000200002.

Behan, B., Connolly, C. G., Datwani, S., Doucet, M., Ivanovic, J., Morioka, R., . Garavan, H. (2014). Response inhibition and elevated parietal-cerebellar correlations in chronic adolescent cannabis users. Neuropharmacology , 84 , 131-137. doi:10.1016/j.neuropharm.2013.05.027.

Galderisi, S., Mucci, A., Bitter, I., Libiger, J., Bucci, P., Fleischhacker, W. W., . Eufest Study Group. (2013). Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial. European Neuropsychopharmacology , 23 , 196-204. doi:10.1016/j.euroneuro.2012.04.019.

Palabras clave.

Meier, M. H., Caspi, A., Ambler, A., Harrington, H., Houts, R., Keefe, R. S., . Moffitt, T. E. (2012). Persistent cannabis users show neuropsychological decline from childhood to midlife. Proceedings of the National Academy of Sciences , 109 , E2657-E2664. doi:10.1073/pnas.1206820109.

Juckel, G., Schlagenhauf, F., Koslowski, M., Wüstenberg, T., Villringer, A., Knutson, B., . Heinz, A. (2006). Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage , 29 , 409-416. doi:10.1016/j.neuroimage.2005.07.051.

Weinberger, D. R. y Berman, K. F. (1996). Prefrontal function in schizophrenia: confounds and controversies. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, 351, 1495-1503.

Fonseca-Pedrero, E., Lucas-Molina, B., Pérez-Albéniz, A., Inchausti, F. y Ortuño-Sierra, J. (2019). Experiencias psicóticas atenuadas y consumo de cannabis en adolescentes de la población general. Adicciones. Avance de publicación on-line. doi:10.20882/adicciones.1149.

San, L., Arranz, B., y Martinez-Raga, J. (2007). Antipsychotic drug treatment of schizophrenic patients with substance abuse disorders. European Addiction Research , 13 , 230-243. doi:10.1159/000104886.

Fornito, A., Yoon, J., Zalesky, A., Bullmore, E. T. y Carter, C. S. (2011). General and specific functional connectivity disturbances in first-episode schizophrenia during cognitive control performance. Biological Psychiatry , 70 , 64-72. doi:10.1016/j.biopsych.2011.02.019.

Kurebayashi, Y. y Otaki, J. (2018). Neurocognitive differences between inpatients and outpatients with symptomatically nonremitted schizophrenia: A cross-sectional study. Perspectives in Psychiatric Care , 54 , 501-506. doi:10.1111/ppc.12257.

García Álvarez, L., Gomar, J. J., García-Portilla, M. P. y Bobes, J. (2019). Consumo de cannabis y alteraciones cognitivas en esquizofrenia y primeros episodios psicóticos. Adicciones , 31 , 89-94. doi:10.20882/adicciones.1328.

Verdejo-Garcia, A. y Bechara, A. (2010). Neuropsychology of executive functions. Psicothema, 22 , 227-235. doi:10.1016/S1575-0973(11)70021-6.

Cannabis, esquizofrenia y cognición, aportes de la conectividad cerebral.

Green, M. F., Nuechterlein, K. H., Gold, J. M., Barch, D. M., Cohen, J., Essock, S., … Marder, S. R. (2004). Approaching a consensus cognitive battery for clinical trials in schizophrenia: The NIMH-MATRICS conference to select cognitive domains and test criteria. Biological Psychiatry , 56 , 301–307. doi:10.1016/j.biopsych.2004.06.023.

Szerman, N., Roncero, C. y Casas, M. (2016). Protocolos de intervención en patología Dual. Barcelona: Edikamed.

Yücel, M., Bora, E., Lubman, D. I., Solowij, N., Brewer, W. J., Cotton, S. M., … Pantelis, C. (2012). The impact of cannabis use on cognitive functioning in patients with schizophrenia: A meta-analysis of existing findings and new data in a first-episode sample. Schizophrenia Bulletin , 38 , 316–330. doi:10.1093/schbul/sbq079.

Skosnik, P. D., Krishnan, G. P., D’souza, D. C., Hetrick, W. P. y O’donnell, B. F. (2014). Disrupted gamma-band neural oscillations during coherent motion perception in heavy cannabis users. Neuropsychopharmacology , 39 , 3087 –3099. doi:10.1038/npp.2014.166.

Rais, M., Van Haren, N. E., Cahn, W., Schnack, H. G., Lepage, C., Collins, L., . Kahn, R. S. (2010). Cannabis use and progressive cortical thickness loss in areas rich in CB1 receptors during the first five years of schizophrenia. European Neuropsychopharmacology , 20 , 855-865. doi:10.1016/j.euroneuro.2010.08.008.

David Antonio Pineda-Salazar Universidad de San Buenaventura Colombia.

Texto completo:

Meyer-Lindenberg, A. (2010). From maps to mechanisms through neuroimaging of schizophrenia. Nature , 468 , 194-202. doi:10.1038/nature09569.

Fusar-Poli, P., Crippa, J. A., Bhattacharyya, S., Borgwardt, S. J., Allen, P., Martin-Santos, R., . Zuardi, A. W. (2009). Distinct effects of ∆9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Archives of General Psychiatry , 66 , 95-105. doi:10.1017/S1461145709990617.

González-Pinto, A., González-Ortega, I., Alberich, S., de Azua, S. R., Bernardo, M., Bioque, M., . y Sánchez-Torres, A. M. (2016). Opposite cannabis-cognition associations in psychotic patients depending on family history. PLoS One , 11 , e0160949. doi:10.1371/journal.pone.0160949.

Colizzi, M. y Bhattacharyya, S. (2017). Does cannabis composition matter? Differential effects of delta-9-tetrahydrocannabinol and cannabidiol on human cognition. Current Addiction Reports, 4 , 62-74. doi:10.1007/s40429-017-0142-2.

Guillermo Alonso Castaño-Pérez Universidad CES Colombia.

Ferraro, L., Russo, M., O’Connor, J., Wiffen, B. D., Falcone, M. A., Sideli, L., . Mondelli, V. (2013). Cannabis users have higher premorbid IQ than other patients with first onset psychosis. Schizophrenia Research , 150 , 129-135. doi:10.1016/j.schres.2013.07.046.

Ringen, P. A., Vaskinn, A., Sundet, K., Engh, J. A., Jonsdottir, H., Simonsen, C., . Andreassen, O. A. (2010). Opposite relationships between cannabis use and neurocognitive functioning in bipolar disorder and schizophrenia. Psychological Medicine , 40 , 1337-1347. doi:10.1017/S0033291709991620.